Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing